|
|
 |
|
Viewing report
|
|
|
|
Pain Drugs: Problems and Opportunities
Centient Consulting, Inc, Sep 2005, Pages: 18
Pain is one of the largest pharmaceutical markets, forecast to reach $25 billion in the next few years, but it has also been plagued by problems including the failure of Vioxx and Celebrex. This report examines the nature of pain, what went wrong with the COX-2 inhibitors, and the alternative approaches and drugs that may fill the resulting void.
Pain comes in many forms and treatments range from non-drug therapies like psychological, surgical and neurostimulus, to analgesics, opiods and even cannabinoids. This report explores these various methods and identifies drugs currently on the market or under development that may replace the COX-2 inhibitors.
Reasons to Purchase
- Understand the nature of pain and why it is a therapeutic challenge
- Identify the companies and the drugs and treatment protocols that are poised to replace the void left by the failure of COX-2 inhibitors
- Analyze the competitive landscape of the $25 billion pain market
Target Audience
- Business development execs/managers seeking partnership opportunities
- Marketing and senior execs/managers wishing to understand the competitive landscape
- Research and development execs/managers wanting to know the current state-of-the-art
- Venture capitalists and fund managers seeking investments
- Analysts and journalists researching the market for treating pain
- Others seeking to understand the driving factors and market dynamics
Drugs Mentioned
- Carbex
- Celebrex
- Codeine
- Imitrex
- Luvox
- Marplan
- Nardil
- Neurontin
- OxyContin
- Parnate
- Paxil
- Prozac
- Topamax
- Tylenol/Acetaminophen
- Vicodin
- Vioxx
- Xyrem
- Zarontin
- Zoloft
- Zomig
|
|
|
|
